Bioinformatics Disease Vaccine 
Drug Target Review
AUGUST 11, 2023
In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. The implications of this finding are far-reaching, as it holds the potential to revolutionize vaccine design.
DrugBaron
NOVEMBER 22, 2022
In 2015, Methuselah Health was founded to investigate the role of proteome instability during ageing, and the extent to which the instability of specific proteins might underlie development of age-related diseases – a concept that arose from the ground-breaking work of Professor Miro Radman (which DrugBaron highlighted previously).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Premier Consulting Blog
JUNE 18, 2023
One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases. However, with rare diseases there may be no available treatments that could serve as SoC or active control in a clinical trial and assigning patients to placebo may be unethical.
Broad Institute
AUGUST 7, 2024
At the Broad, he directs the Cancer Genome Computational Analysis Group , and he is a professor of pathology at Harvard Medical School and director of bioinformatics at Massachusetts General Hospital. Anna Greka ’s research focuses on fundamental mechanisms of cellular dysfunction in genetic diseases with a focus on membrane proteins.
Drug Target Review
SEPTEMBER 30, 2024
is its relation to the disease well figured out and validated? Dr Ofran received a PhD with distinction in Molecular Biophysics and Biomedical Informatics from Columbia University and was a professor of bioinformatics and molecular research at Bar-Ilan University. Is there still an unmet need? Can our technology solve the problem?
Drug Target Review
DECEMBER 28, 2023
Recent advances in bioinformatics show clonal neoantigens are the best targets for immunotherapy, as I will elucidate below. Patients with high numbers of clonal neoantigens show improved disease-free survival. These mutations are called clonal mutations or clonal neoantigens.
Agency IQ
OCTOBER 12, 2023
Joneckis said that CBER has “some limited uses that we have seen in external submissions, mostly in the bioinformatics area,” but not as many as CDER. Regarding artificial intelligence (AI), an important topic at RAPS Convergence, the two centers discussed external and internal use cases.
Expert insights. Personalized for you.
98 
Let's personalize your content